Search Results for "Chemotherapy"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for Chemotherapy. Results 61 to 70 of 220 total matches.
Peripheral-Blood Stem-Cells Transplants
The Medical Letter on Drugs and Therapeutics • Aug 18, 1995 (Issue 955)
FOR
ONLINE USERS
PERIPHERAL-BLOOD STEM-CELL TRANSPLANTATION
High-dose chemotherapy, with or without total ...
High-dose chemotherapy, with or without total body radiation, followed by bone marrow transplantation to restore bone marrow function has been used widely in the treatment of malignant diseases in recent years (Medical Letter, 34:79, 1992; 37:25, 1995). Now, however, instead of using bone marrow itself to restore function destroyed by chemotherapy and radiation, many centers infuse hematopoietic stem cells harvested from peripheral blood. Most stem cell transplants have been autologous; allogeneic stem cells have been tried in a small number of patients (WI Bensinger et al, Blood,...
Enfortumab Vedotin (Padcev) for Urothelial Cancer (online only)
The Medical Letter on Drugs and Therapeutics • May 22, 2023 (Issue 1677)
chemotherapy. Accelerated approval was based on
tumor response rates and the durability of response ...
Enfortumab vedotin-ejfv (Padcev – Astellas), a
nectin-4-directed antibody and microtubule inhibitor
conjugate, has received accelerated approval
from the FDA for use with the immune checkpoint
inhibitor pembrolizumab (Keytruda) for treatment
of locally advanced or metastatic urothelial cancer
in adults who are ineligible for cisplatin-containing
chemotherapy. Accelerated approval was based on
tumor response rates and the durability of response.
Med Lett Drugs Ther. 2023 May 22;65(1677):e91-2 doi:10.58347/tml.2023.1677g | Show Introduction Hide Introduction
Gefitinib (Iressa) for advanced non-small cell lung cancer
The Medical Letter on Drugs and Therapeutics • Sep 02, 2002 (Issue 1138)
failed 1 or 2 previous
chemotherapy regimens, at least 1 of which contained a platinum derivative like ...
Patients with lung cancer may be asking their physicians about gefitinib (ge fi' tye nib; ZD1839; Iressa -- AstraZeneca), because it has been the subject of positive coverage in the media. An inhibitor of the epidermal growth factor receptor (EGFR) tyrosine kinase, this oral drug has not been approved by the FDA, but is in clinical trials in the US for treatment of non-small cell lung cancer (NSCLC) and some other solid tumors. Iressa was recently approved in Japan, and is available from the manufacturer on a "compassionate-use" basis in the US (800-236-9933).
In Brief: Avelumab (Bavencio) for Metastatic Merkel Cell Carcinoma (online only)
The Medical Letter on Drugs and Therapeutics • Jul 17, 2017 (Issue 1525)
months with chemotherapy. MCC
tumors, which often express PD-L1, have been treated offlabel
with the PD ...
The FDA has approved the fully-human programmed death ligand 1 (PD-L1) blocking antibody avelumab (Bavencio – EMD Serono/Pfizer) for treatment of metastatic Merkel cell carcinoma (MCC) in patients ≥12 years old. Avelumab is the first drug to be approved in the US for this rare skin cancer. About 1600 people in the US, most commonly older adults (mean age at presentation is 75 years), are diagnosed each year with MCC. Most of these patients can be treated with surgical resection, but ~50% will have a recurrence and >30% will eventually have metastatic disease. Median progression-free...
In Brief: Severe Hypersensitivity Reactions with Rolapitant IV Emulsion (Varubi)
The Medical Letter on Drugs and Therapeutics • Jan 29, 2018 (Issue 1539)
for adjunctive prevention of delayed nausea
and vomiting associated with cancer chemotherapy in
adults2; the IV ...
The FDA has warned that the IV emulsion formulation of the substance P/neurokinin 1 (NK1) receptor antagonist rolapitant (Varubi) has been associated in postmarketing reports with serious hypersensitivity reactions including anaphylaxis and anaphylactic shock.1 Rolapitant was approved by the FDA as an oral tablet in 2015 for adjunctive prevention of delayed nausea and vomiting associated with cancer chemotherapy in adults2; the IV emulsion formulation of the drug was approved for the same indication in 2017.The reported hypersensitivity reactions occurred during or shortly after infusion of...
Iodine-131 Tositumomab (Bexxar) for Treatment of Lymphoma
The Medical Letter on Drugs and Therapeutics • Oct 27, 2003 (Issue 1168)
, external beam radiation
and conventional chemotherapy. Biologic agents such as interferon-alfa, rituximab ...
Bexxar, a combination of the monoclonal antibody tositumomab and radiolabeled Iodine-131 tositumomab (Corixa Corp/GlaxoSmithKline) has been approved by the FDA for a single treatment of relapsed follicular non-Hodgkin's lymphoma (NHL) in patients who are refractory to rituximab (Rituxan - Medical Letter 1998; 40:65). It is the second radioimmunoconjugate to be approved for refractory NHL; yttrium-90 linked to ibritumomab tiuxetan (Zevalin) was approved in 2002. Tositumomab, like ibritumomab, is a monoclonal antibody of mouse origin that binds to the CD20 antigen present on the surface of >90%...
Nabilone And Other Antiemetic For Cancer Patients
The Medical Letter on Drugs and Therapeutics • Jan 01, 1988 (Issue 756)
, was recently marketed in the USA for oral treatment of nausea and vomiting associated with cancer chemotherapy ...
Nabilone (Cesamet - Lilly), a synthetic cannabinoid chemically related to tetrahydrocannabinol (THC), the main active ingredient in marijuana, was recently marketed in the USA for oral treatment of nausea and vomiting associated with cancer chemotherapy. Oral THC itself, known generically as dronabinol (Marinol), is also commercially available as an antiemetic for cancer patients (Medical Letter, 27:97, 1985). Other drugs used for this purpose include metoclopramide (Reglan - Medical Letter, 24:67, 1982), prochlorperazine (Compazine; and others), haloperidol (Haldol; and others), and...
Pemetrexed (Alimta) for Mesothelioma
The Medical Letter on Drugs and Therapeutics • Apr 12, 2004 (Issue 1180)
is the first chemotherapy regimen approved by the FDA for treatment of malignant pleural mesothelioma ...
The combination of pemetrexed (Alimta - Lilly) and cisplatin is the first chemotherapy regimen approved by the FDA for treatment of malignant pleural mesothelioma. This uncommon malignancy, which has been linked to asbestos exposure, was previously considered unresponsive to chemotherapy, with a median survival of 6-8 months from diagnosis (VW Rusch, J Clin Oncol 2003; 21:2629).
Fruquintinib (Fruzaqla) for Metastatic Colorectal Cancer (online only)
The Medical Letter on Drugs and Therapeutics • Feb 19, 2024 (Issue 1696)
cancer (mCRC)
who received prior fluoropyrimidine-, oxaliplatin-, and
irinotecan-based chemotherapy ...
Fruquintinib (Fruzaqla – Takeda), an oral kinase
inhibitor, has been approved by the FDA for treatment
of adults with metastatic colorectal cancer (mCRC)
who received prior fluoropyrimidine-, oxaliplatin-, and
irinotecan-based chemotherapy, anti-VEGF therapy,
and, in patients with RAS wild-type mutations, anti-EGFR therapy. The drug can be used in patients with
mCRC regardless of biomarker status. Fruquintinib
is the first drug to become available in the US for
treatment of mCRC that targets 3 VEGF receptor
kinases.
Med Lett Drugs Ther. 2024 Feb 19;66(1696):e34-5 doi:10.58347/tml.2024.1696f | Show Introduction Hide Introduction
Tarlatamab (Imdelltra) for Small Cell Lung Cancer (online only)
The Medical Letter on Drugs and Therapeutics • Jul 08, 2024 (Issue 1706)
cell lung cancer (SCLC) in adults who had
disease progression on or after platinum-based
chemotherapy ...
Tarlatamab-dlle (Imdelltra – Amgen), a first-in-class
bispecific delta-like ligand 3 (DLL3)-directed CD3
T-cell engager, has received accelerated approval
from the FDA for treatment of extensive-stage
small cell lung cancer (SCLC) in adults who had
disease progression on or after platinum-based
chemotherapy. It is the first bispecific DLL3-directed
CD3 T-cell engager to be approved in the US for this
indication. Most patients with SCLC have a response
to initial treatment, but progression generally
occurs within a few months and overall survival is
usually less than 8 months....
Med Lett Drugs Ther. 2024 Jul 8;66(1706):e113-4 doi:10.58347/tml.2024.1706c | Show Introduction Hide Introduction